The hemophilia B treatment Idelvion is soon expected to be reimbursed in Korea, with CSL Behring completing drug pricing negotiations for the drug with the regulatory authorities.

The drug’s advantage is in its convenience in administration, as it can be administered once every 1 to 3 weeks.

According to industry sources on the 12th, the National Health Insurance Service recently disclosed that it has completed drug pricing negotiations for Idelvion. The NHIS has been disclosing its drug pricing negotiation results since April.

Idelvion Inj had been in drug price negotiations since April after passing the Health Insurance Review and Assessment Service’s Drug Reimburseme